SAFETY DATA SHEET



1. Identification

Product identifier Erbitux®

Other means of identification

Item CodeVL7676, VL7709LY NumberLY2939777Recommended usePharmaceuticalRecommended restrictionsNone known.

Manufacturer/Importer/Supplier/Distributor information

Manufacturer

Company name Eli Lilly and Company
Address Lilly Corporate Center
Indianapolis. IN 46285

United States

Telephone Phone: +1-317-276-2000

E-mail lilly msds@lilly.com

Emergency phone number CHEMTREC: +1-800-424-9300

2. Hazard(s) identification

Physical hazards Not classified.

Health hazards Not classified.

OSHA defined hazards Not classified.

Label elements

Hazard symbol None.
Signal word None.

Hazard statement The mixture does not meet the criteria for classification.

Precautionary statement

PreventionNot available.ResponseNot available.StorageNot available.DisposalNot available.

Hazard(s) not otherwise

classified (HNOC)

None known.

Supplemental information None.

3. Composition/information on ingredients

Mixtures

Chemical name	Common name and synonyms	CAS number	%
Cetuximab	C225	Mixture	<1
	IMC_C225		

Composition comments Remaining components of this product are non-hazardous and/or are present at concentrations

below reportable levels.

4. First-aid measures

Inhalation Call a physician if symptoms develop or persist.

Skin contact Rinse skin with water/shower. Get medical attention if irritation develops and persists.

Eye contact In case of eye contact, remove contact lens and rinse immediately with plenty of water, also under

the eyelids, for at least 15 minutes. Get medical attention if irritation develops and persists.

Ingestion Get medical attention if symptoms occur.

Material name: Erbitux® SDS US

5198 Version #: 04 Revision date: 02-19-2019 Issue date: 09-21-2015

Most important

symptoms/effects, acute and

delayed

Indication of immediate medical attention and special

treatment needed

The following adverse effects have been noted with therapeutic use of this material: Rash.

Hypersensitivity reactions. Allergic reactions have been reported.

General information If you feel unwell, seek medical advice (show the label where possible).

5. Fire-fighting measures

Suitable extinguishing media

Unsuitable extinguishing

media

Use fire-extinguishing media appropriate for surrounding materials.

Not available.

Not available.

Specific hazards arising from

the chemical

Not applicable.

Special protective equipment and precautions for firefighters

Wear suitable protective equipment.

General fire hazards This product is an aqueous mixture which will not burn.

6. Accidental release measures

Personal precautions, protective equipment and emergency procedures

Avoid inhalation of mists or aerosols.

Methods and materials for containment and cleaning up

Use absorbent/adsorbent material to solidify liquids. Clean up promptly by sweeping or vacuum.

Wear appropriate protective equipment and clothing during clean-up.

Environmental precautions Avoid release to the environment.

7. Handling and storage

Precautions for safe handling

Conditions for safe storage, including any incompatibilities

Not available.

Storage temperature: between 2 C and 8 C. Keep container tightly closed in a dry and

well-ventilated place.

8. Exposure controls/personal protection

Biological limit values Exposure guidelines No biological exposure limits noted for the ingredient(s). Occupational Exposure Limit (OEL): Not established

Preliminary guidance: Control exposures to between 20 ug/m3 and 100 ug/m3 until an OEL is

established.

Appropriate engineering

controls

Contained handling practices preferred. If open handling is necessary, use control measures (i.e. ventilated enclosure, local exhaust ventilation) to maintain airborne levels below the occupational

exposure level (OEL).

Individual protection measures, such as personal protective equipment

Eye/face protection Safety glasses with side shields recommended. If splash potential or dusty operations, wear

goggles/faceshield.

Skin protection

Hand protection Chemical resistant gloves.

Other While monoclonal antibodies are not anticipated to be readily absorbed through the skin, wear

impervious gloves and body covering (i.e. lab coat) to minimize skin contact.

Respiratory protection If the applicable occupational exposure level (OEL) is anticipated to be exceeded, wear an

approved respirator with sufficient protection factor to control exposure below the OEL.

Thermal hazards Not available.

General hygiene considerations

Engineering controls should be used as the primary means to control workplace exposures. Follow good workplace hygiene practices such as washing hands after handling this material.

This substance is a monoclonal antibody. Based on the biophysical properties and absorption characteristics of monoclonal antibodies, oral and dermal routes of exposure are not considered occupationally relevant and potential bioavailability through inhalation is minimal.

9. Physical and chemical properties

Appearance Clear. Solution.

Physical state Liquid.
Form Liquid.

Material name: Erbitux® SDS US

5198 Version #: 04 Revision date: 02-19-2019 Issue date: 09-21-2015

Color Colorless
Odor Not available.
Odor threshold Not available.
pH 5.3 - 5.7

Melting point/freezing point Not available.

Initial boiling point and boiling Not available.

range

Flash point Not available.

Evaporation rate Not available.

Flammability (solid, gas) Not applicable.

Upper/lower flammability or explosive limits

Flammability limit - lower

Not available.

(%)

Flammability limit - upper

Not available.

(%)

Explosive limit - lower (%) Not available.

Explosive limit - upper (%) Not available.

Vapor pressure Not available.

Vapor density Not available.

Relative density Not available.

Solubility(ies)

Solubility (water) Not available.

Partition coefficient Not available.

(n-octanol/water)

Auto-ignition temperatureNot available.Decomposition temperatureNot available.ViscosityNot available.

Other information

Explosive properties Not explosive.

Oxidizing properties The substance or mixture is not classified as oxidizing.

10. Stability and reactivity

Reactivity Not water reactive.

Chemical stability Material is stable under normal conditions.

Possibility of hazardous Hazardous polymerization does not occur.

reactions

Conditions to avoidNone under normal conditions.

Incompatible materials Strong oxidizing agents.

Hazardous decomposition

products

No hazardous decomposition products are known.

11. Toxicological information

Information on toxicological effects

Acute toxicity Not available.

Skin corrosion/irritation

Due to lack of data the classification is not possible.

Serious eye damage/eye

Due to lack of data the classification is not possible.

irritation

Respiratory or skin sensitization

Respiratory sensitizationDue to lack of data the classification is not possible. **Skin sensitization**Due to lack of data the classification is not possible.

Germ cell mutagenicityResult in genetic toxicity assays (in vitro and in vivo): Negative
Based on available data, the classification criteria are not met.

Material name: Erbitux® SDS US

Carcinogenicity

No carcinogenicity data available for this product. Not listed by IARC, NTP, ACGIH or OSHA. Due to lack of data the classification is not possible.

to lack of data the classification is not possible.

IARC Monographs. Overall Evaluation of Carcinogenicity

Not listed.

OSHA Specifically Regulated Substances (29 CFR 1910.1001-1052)

Not regulated.

US. National Toxicology Program (NTP) Report on Carcinogens

Not listed.

Reproductive toxicity

Experiments have shown reproductive toxicity effects on laboratory animals. Embryo-lethality.

Menstrual irregularities. (intravenous)

Based on animal models, EGFR is involved in prenatal development and may be essential for

normal organogenesis, proliferation, and differentiation in the developing embryo.

Based on available data, the classification criteria are not met.

Specific target organ toxicity -

single exposure

Due to lack of data the classification is not possible.

Specific target organ toxicity -

repeated exposure

Animal studies have reported the following effects: Skin. Rash. Kidney effects. (intravenous)

Based on available data, the classification criteria are not met.

Aspiration hazard Not applicable.

Further information

The following adverse effects have been noted with therapeutic use of this material: Rash.

Hypersensitivity reactions. Allergic reactions have been reported.

This substance is a monoclonal antibody. Based on the biophysical properties and absorption characteristics of monoclonal antibodies, oral and dermal routes of exposure are not considered occupationally relevant and potential bioavailability through inhalation is minimal.

12. Ecological information

Ecotoxicity Not expected to be harmful to aquatic organisms.

Persistence and degradability
Bioaccumulative potential
Mobility in soil
Other adverse effects
Not available.
Not available.
Not available.

13. Disposal considerations

Disposal instructions Dispose in accordance with all applicable regulations.

14. Transport information

DOT

Not regulated as dangerous goods.

IATA

Not regulated as dangerous goods.

IMDG

Not regulated as dangerous goods.

Transport in bulk according to

Not available.

Annex II of MARPOL 73/78 and

the IBC Code

15. Regulatory information

US federal regulations This product is not known to be a "Hazardous Chemical" as defined by the OSHA Hazard

Communication Standard, 29 CFR 1910.1200.

Toxic Substances Control Act (TSCA)

TSCA Section 12(b) Export Notification (40 CFR 707, Subpt. D)

Not regulated.

CERCLA Hazardous Substance List (40 CFR 302.4)

Not listed

SARA 304 Emergency release notification

Not regulated.

Material name: Erbitux® SDS US

OSHA Specifically Regulated Substances (29 CFR 1910.1001-1052)

Not regulated.

Superfund Amendments and Reauthorization Act of 1986 (SARA)

SARA 313 (TRI reporting)

Not regulated.

Other federal regulations

Clean Air Act (CAA) Section 112 Hazardous Air Pollutants (HAPs) List

Not regulated.

Clean Air Act (CAA) Section 112(r) Accidental Release Prevention (40 CFR 68.130)

Not regulated.

International Inventories

Country(s) or regionInventory nameOn inventory (yes/no)*CanadaDomestic Substances List (DSL)NoCanadaNon-Domestic Substances List (NDSL)NoUnited States & Puerto RicoToxic Substances Control Act (TSCA) InventoryNo

16. Other information, including date of preparation or last revision

 Issue date
 09-21-2015

 Revision date
 02-19-2019

Version # 04

Disclaimer As of the date of issuance, we are providing available information relevant to the handling of this

material in the workplace. All information contained herein is offered with the good faith belief that it is accurate. THIS SAFETY DATA SHEET SHALL NOT BE DEEMED TO CREATE ANY WARRANTY OF ANY KIND (INCLUDING WARRANTY OF MERCHANT ABILITY OR FITNESS FOR A PARTICULAR PURPOSE). In the event of an adverse incident associated with this material, this safety data sheet is not intended to be a substitute for consultation with appropriately trained personnel. Nor is this safety data sheet intended to be a substitute for product literature

which may accompany the finished product.

For additional information contact:

Eli Lilly and Company Hazard Communication +1-317-651-9533

Material name: Erbitux® sps us

5198 Version #: 04 Revision date: 02-19-2019 Issue date: 09-21-2015

^{*}A "Yes" indicates that all components of this product comply with the inventory requirements administered by the governing country(s)

A "No" indicates that one or more components of the product are not listed or exempt from listing on the inventory administered by the governing country(s).